Liu Chen-Chung 劉震鐘 – NTU Neuroscience

劉震鐘

Chen-Chung Liu

Lab Introduction & Major Research Interests

As a psychiatrist with heavy clinical loads, my main research interests focus on the putative pre-psychotic state and early stage of psychosis. During past 12 years, our team in schizophrenia research has followed up a cohort of this heterogeneous population to investigate what might be happening around the incipient of psychosis from clinical, neurocognitive, neurobiological, and even genetic perspectives. Currently more efforts are invested in clinical trials for novel agents aiming at treating negative symptoms and cognitive symptoms of schizophrenia. My role in our research team is 1) mental health education/campaign for case recruitment; 2) clinical follow-up for patients at early stage of psychosis; 3) continuing observation on a longitudinal cohort, including retrieving those who lost of follow-up from our system; 4) participating in study design and execution of clinical trials testing new agents; 5) initiating a new observational study regarding “guided dose reduction” of antipsychotic treatment in a group of remitted psychosis patients; while these patients may serve as participants in relevant neurocognitive studies on this special population.

Recent Representative Publication ( * corresponding author)

1. Chen-Chung Liu*, Mau-Sun Hua, Tzung-Jeng Hwang, Chien-Yeh Chiu, Chih-Min Liu, Ming H. Hsieh, Yi-Ling Chien, Yi-Ting Lin, Hai-Gwo Hwu. Neurocognitive functioning of subjects with putative pre-psychotic states and early psychosis. Schizophrenia Research. 2015; 164: 40-46

2. Chen-Chung Liu*, Arsime Demjaha. Antipsychotic interventions in prodromal psychosis: safety issues. CNS Drugs. 2013; 27:197-205

3. Liu CC, Tien YJ, Chen CH, Chiu YN, Chien YL, Hsieh MH, Liu CM, Hwang TJ, Hwu HG.* Development of a brief self-report questionnaire for screening putative pre-psychotic states. Schizophrenia Research. 2013; 143: 32-37

4. Fusar-Poli P*, Cappucciati M, Borgwardt S, Woods SW, Addington J, Nelson B, Nieman DH, Stahl D, Bonoldi I, Rutigliano G, Riecher-RÖssler A, Simon AE, Mizuno M, Lee TY, Kwon JS, Lam M, Perez J, Keri S, Amminger GP, Metzler S, Kawohl W, Rossler W, Lee J, Labad J, Ziermans T, An SK, Liu CC, Woodberry K, Braham A, Corcoran CM, McGorry P, Yung AR, McGuire P. Heterogeneity of psychosis risk within individuals at clinical high risk. JAMA Psychiatry. 2016; (73) 113-120

5. Ricardo P. Garay*, Leslie Citrome, Ludovic Samalin, Chen-Chung Liu, Morten S. Thomsen, Christoph U. Correll, Ahcène Hameg, Pierre-Michel Llorca. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion on Pharmacotherapy. 2016;17(7):921-36.